Anti-Human BCMA/TNFRSF17 Reference Antibody (Ispectamab, RUO) (HX959076)

Name: Anti-Human BCMA/TNFRSF17 Reference Antibody (Ispectamab, RUO)
Brand: abinScience
SKU: HX959076
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HX959076
Description	Ispectamab (HX959076) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Host species	Human
Clonality	Monoclonal
Isotype	IgG1-kappa
Tested applications	WB
Target	B-cell maturation protein, BCM, BCMA, CD269, TNFRSF17, Tumor necrosis factor receptor superfamily member 17
Endotoxin level	< 10 EU/mg
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q02223
Form	Liquid
Storage buffer	0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	BMS-986352, CC-99712, CC99712, CC99712, SP8919, 2413386-21-5
Background	Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli).
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Western blot

Western blot analysis was performed using anti-CD269 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD269 (Catalog No: HX959012)
Lane 2: negative control
SDS-PAGE

SDS-PAGE for Research Grade Ispectamab.
Bioactivity

Detects recombinant human CD269/TNFRSF17/BCMA (Catalog No: HX959012) in indirect ELISA